Segmented Gamma-Hydroxybutyrate Formulation for Once-Nightly Narcolepsy Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current modified release formulations of sodium oxybate for narcolepsy have low bioavailability and require twice-nightly administration, which is inconvenient and can disrupt sleep.
Innovation Solution
A modified release formulation of gamma-hydroxybutyrate that rapidly releases half of its dose in acidic conditions and the other half in phosphate buffer, allowing for once-nightly administration with improved bioavailability and pharmacokinetic profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If modified release formulations of sodium oxybate are used, then once-nightly administration is achieved, but bioavailability is reduced
Solution Approach 1:
The formulation is divided into two distinct portions: an immediate release portion and a modified release portion. This segmentation allows different parts of the dosage form to serve different functions - the immediate release portion provides rapid absorption for high bioavailability, while the modified release portion extends duration for once-nightly administration.
Solution Approach 2:
The patent utilizes pH-dependent dissolution characteristics by formulating with compounds that have different solubility profiles at different pH levels. The immediate release portion dissolves rapidly in gastric acid, while the modified release portion dissolves more slowly in intestinal pH, optimizing both bioavailability and duration of action.
2Ease of operation
If modified release formulations of sodium oxybate are used, then once-nightly administration is achieved, but therapeutic effectiveness is reduced
Solution Approach 1:
The segmented formulation ensures that the immediate release portion provides rapid therapeutic effect upon administration, while the modified release portion maintains therapeutic levels throughout the night, achieving both convenience and effectiveness.
Solution Approach 2:
The modified release portion provides continuous drug release throughout the night, maintaining therapeutic effectiveness without requiring a second dose, thus enabling once-nightly administration while preserving therapeutic action.
3Reliability
If twice-nightly administration is required, then bioavailability is improved, but sleep disruption occurs
Solution Approach 1:
The modified release portion provides continuous drug release throughout the night, maintaining therapeutic levels without requiring interruption for a second dose, thus eliminating sleep disruption while preserving bioavailability.
Solution Approach 2:
The immediate release portion provides rapid initial absorption to achieve therapeutic levels quickly, allowing the patient to fall asleep without requiring a second dose later in the night.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves bioavailability comparable to twice-nightly immediate release solutions, with reduced side effects and improved therapeutic effectiveness, allowing for effective treatment of narcolepsy symptoms with fewer adverse reactions.
Implementation Method 1
The formulation achieves bioavailability comparable to twice-nightly immediate release solutions, with reduced side effects and improved therapeutic effectiveness
Data Source
AI summary
Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.